Clinical Trial Update: An Observational Study of RoActemra/Actemra (Tocilizumab) in Smoking Versus Non-Smoking Patients With Rheumatoid Arthritis

View source ↗

Summary

An observational study evaluating smoking vs. non-smoking rheumatoid arthritis patients treated with tocilizumab (RoActemra/Actemra) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Actemra (tocilizumab)
• RoActemra (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Status: COMPLETED